Here's another case in the recording I did with Drs. Jyoti Patel from Northwestern and Bob Doebele from University of Colorado, discussing a series of...
Yesterday afternoon, the FDA approved the ALK inhibitor crizotinib, newly christened as XALKORI, for patients with locally advanced or metastatic...
ALERT: The links for the podcasts are now fixed. Here's the question and answer session with Drs. Mary Pinder and Nasser Hanna following their...
The answer is, "Usually pretty early". I tell my patients that the risk is "front-loaded", meaning that we typically see recurrences occur in the...
The FLEX trial, a European study of cisplatin/Navelbine (vinorelbine) with or without the monoclonal antibody against EGFR Erbitux (cetuximab), was a...
One of the longstanding ideas in lung cancer management is that you exhaust the benefit of first line combination chemotherapy after 4-6 cycles of treatment.
A few months ago I wrote about the preliminary reported results from the AVAPERL trial, which started patients with previously untreated advanced nonsquamous NSCLC up to four cycles of cisplatin/Alimta (pemetrexed)/Avastin (bevacizumab), then randomized patients who hadn't progressed after four cycles to either maintenance Alimta/Avastin or Avastin alone. At the Eurpean Society for Medical Oncology (ESMO) 2011 meeting,
It's been a while since we released another podcast from the recording I did with Drs. Jyoti Patel from Northwestern and Bob Doebele from University of Colorado earlier this year. In that session, we covered a series of real life scenarios in managing lung cancer that are at the outer limits of what we can say we know and leave us relying more on our best judgment than on evidence. Along with the comments by Drs. Patel and Doebele, we've then added responses from a collection of additional great lung cancer experts (Drs.
Here's the podcast from the recent webinar by Dr. David Yankelevitz, Professor of Radiology at Mount Sinai Medical Center in New York City, on the subject of "Pulmonary Nodules: Evaluation and Management".
We've covered the potential value of systemic therapy for early stage NSCLC in a wide range of posts and podcasts, and to summarize what we've learned in a sentence, it's basically that chemotherapy can significantly increase progression-free survival (PFS) and overall survival (OS) in patients who have undergone curative surgery for stage I-III NSCLC, but the benefit is far more convincing in patients with a high enough risk to justify the potential adverse effects of chemotherapy.
It's not uncommon for a question here to be about the a pathologist's terminology on a report that equivocates about whether a lesion is bronchioloalveolar carcinoma (BAC) or another form of adenocarcinoma, perhaps "well-differentiated adenocarcinoma", especially if it has a radiographic appearance of a hazy infiltrate or many small ground glass opacities.
Following the terrific presentations by Drs. Ben Solomon and Ross Camidge on the science and clinical experience with the novel ALK inhibitor XALKORI (crizotinib), we had a question and answer session, which is now available as a podcast. Here's the audio podcast and transcript for it (not really a video component for this one).
[powerpress]
The National Lung Screening Trial (NLST), a protocol with over 50,000 former or current smokers between ages 55 and 75, justifiably became a major news story when the results demonstrated a significant improvement in lung cancer-specific and all-cause mortality of 20% and 6.7%, respectively.
Almost two months ago, I wrote about stage IV NSCLC in the elderly. There, I reviewed existing data and focused on the published results of the French study (IFCT-050, aka Quoix study) that showed that elderly patients, just like younger patients, do better with platinum-doublet regimens in the first line than with one drug.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
